Good evening :)
$
₹
Rallybio Corp

Rallybio Corp

RLYB

NASDAQ
Asset Logo

Rallybio Corp

RLYB

NASDAQ
$16.931.48% (-0.25)
$
₹
$16.931.48% (-0.25)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $91.3M the stock is ranked 4745

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

2.15
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.96
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$7.99
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

7051.24%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 4 analysts' reports

Buy
1 analyst
Hold
3 analysts
Sell
0 analyst

Analysts expect a -53.46% price downside over the next year

Current Price$16.93
Target Price$8

Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
74.56
74.56
1Y Return
19.79%
19.79%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.98
23.98
1Y Return
38.66%
38.66%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
32.8%
32.8%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.58
29.58
1Y Return
31.31%
31.31%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.41
19.41
1Y Return
31.25%
31.25%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Rallybio Corp 2.150.96-
AbbVie Inc74.5650.450.54
Amgen Inc23.9817.832.32

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

0.2
16
0.2
-5.8
0.2
-8.2
43.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00.290.290.030.210.210.210.220.210
Net Income-19.02-16.23-11.46-11.04-9.43-9.7016.01-5.85-8.2743.66
Net Profit Margin--5430.10%-3834.78%-29063.15%-4452.35%-4576.88%7554.71%-2636.03%-3904.71%-
See CostsAll values in $ Million

Frequently asked questions

  1. Rallybio Corp (RLYB) share price today is $16.93 as of September 21, 2026 at 8:24 PM IST. The stock touched a day high of $17.14 and a day low of $16.85.

  2. Rallybio Corp stock trades on NASDAQ under the ticker symbol RLYB.

  3. Rallybio Corp's market capitalization is $91.32M as of September 21, 2026 at 8:24 PM IST.

  4. Rallybio Corp's price-to-earnings (P/E) ratio is 2.15 as of September 21, 2026.

  5. Rallybio Corp's price-to-book (P/B) ratio is 0.96 as of September 21, 2026.

  6. Yes, You can buy Rallybio Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Rallybio Corp shares in three steps: 1. Search Rallybio Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Rallybio Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Rallybio Corp (RLYB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.5904 shares at the current price of $16.93.

Loading...